Januvia is a prescription medication used to treat type 2 diabetes. It belongs to a class of drugs called dpp-4 inhibitors. The drug works by blocking the enzyme dipeptidyl peptidase-4 that breaks down incretin hormones. Inhibition of this enzyme increases levels of incretins that stimulate insulin release. It also reduces glucagon secretion which lowers blood glucose after meals. The combined effect helps lower blood sugar without causing hypoglycemia when used alone. It is taken orally once daily as part of a broader treatment plan.

Januvia is a prescription medication used to manage type 2 diabetes. Its active ingredient, sitagliptin, belongs to a class of drugs called dipeptidyl peptidase-4 inhibitors. These inhibitors enhance the activity of incretin hormones that stimulate insulin release and reduce glucagon secretion. By increasing the availability of glp-1 and gip, Januvia helps lower blood glucose levels after meals. The drug works by selectively blocking the enzyme that breaks down these hormones, leading to prolonged signaling. This targeted action improves glycemic control without causing excessive insulin secretion, reducing the risk of hypoglycemia. Clinical studies have shown that Januvia effectively lowers hemoglobin a1c by about 0.5 to 0.8 percent on average. The medication is taken orally and is generally well tolerated with a low incidence of side effects.

The most common side effects include mild headache. Temporary fatigue may also be reported. Occasional nausea can occur. Skin irritation is sometimes observed. Mild dizziness may appear. These reactions are generally short lived.

The most frequently reported side effects are mild and temporary. These often include headache and dizziness. Some people experience nausea or fatigue. Muscle aches may also occur occasionally. Mild fever is another symptom that can appear. Skin redness or irritation is sometimes observed. These reactions typically resolve without intervention. Serious complications are rare.